Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy

Authors: Xiaoxiang Guan, Ming Yin, Qingyi Wei, Hui Zhao, Zhensheng Liu, Li-E Wang, Xianglin Yuan, Michael S O'Reilly, Ritsuko Komaki, Zhongxing Liao

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer. We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients.

Methods

We genotyped three potentially functional VEGF variants [-460 T > C (rs833061), -634 G > C (rs2010963), and +936 C > T (rs3025039)] and estimated haplotypes in 124 Caucasian patients with LA-NSCLC treated with definitive radiotherapy. We used Kaplan-Meier log-rank tests, and Cox proportional hazard models to evaluate the association between VEGF variants and overall survival (OS).

Results

Gender, Karnofsky's performance scores (KPS) and clinical stage seemed to influence the OS. The variant C genotypes were independently associated with significantly improved OS (CT+CC vs. TT: adjusted hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.37-0.92, P = 0.022), compared with the VEGF -460 TT genotype.

Conclusions

Our study suggests that VEGF -460 C genotypes may be associated with a better survival of LA-NSCLC patients after chemoradiotherapy. Large studies are needed to confirm our findings.
Appendix
Available only for authorised users
Literature
1.
Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005, 128 (1): 452-462. 10.1378/chest.128.1.452.CrossRefPubMed
2.
Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999, 17 (10): 3188-3194.PubMed
3.
Jeremic B, Shibamoto Y, Acimovic L, Djuric L: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995, 13 (2): 452-458.PubMed
4.
Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD: The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009, 8 (9): 2496-2508. 10.1158/1535-7163.MCT-09-0302.CrossRefPubMedPubMedCentral
5.
Langer C, Soria JC: The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 11 (2): 82-90. 10.3816/CLC.2010.n.011.
6.
Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, Yang PC: Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer. 2000, 89 (6): 475-483. 10.1002/1097-0215(20001120)89:6<475::AID-IJC2>3.0.CO;2-T.CrossRefPubMed
7.
Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ, Landreneau RJ: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001, 8 (1): 72-79. 10.1007/s10434-001-0072-y.CrossRefPubMed
8.
Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H, Fukurchi Y: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung. 2005, 183 (1): 29-42. 10.1007/s00408-004-2521-4.CrossRefPubMed
9.
Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, Asomaning K, Lynch TJ, Wain JC, Christiani DC: VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2008, 26 (6): 856-862. 10.1200/JCO.2007.13.5947.CrossRefPubMed
10.
Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW: Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003, 63 (4): 812-816.PubMed
11.
Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000, 12 (8): 1232-1235. 10.1006/cyto.2000.0692.CrossRefPubMed
12.
Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E: A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000, 37 (6): 443-448. 10.1159/000054076.CrossRefPubMed
13.
Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD: Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 2009, 27 (20): 3370-3378. 10.1200/JCO.2008.20.6763.CrossRefPubMedPubMedCentral
14.
Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, Son JW, Kim CH, Lee WK, Kam S: Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14 (3): 571-575. 10.1158/1055-9965.EPI-04-0472.CrossRefPubMed
15.
Zhai R, Liu G, Zhou W, Su L, Heist RS, Lynch TJ, Wain JC, Asomaning K, Lin X, Christiani DC: Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res. 2008, 14 (2): 612-617. 10.1158/1078-0432.CCR-07-1655.CrossRefPubMed
16.
Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS, Jun SH: Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res. 2008, 14 (1): 62-66. 10.1158/1078-0432.CCR-07-1537.CrossRefPubMed
17.
Hefler LA, Mustea A, Konsgen D, Concin N, Tanner B, Strick R, Heinze G, Grimm C, Schuster E, Tempfer C: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res. 2007, 13 (3): 898-901. 10.1158/1078-0432.CCR-06-1008.CrossRefPubMed
18.
Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W: Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005, 11 (10): 3647-3653. 10.1158/1078-0432.CCR-04-1803.CrossRefPubMed
19.
Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, Ruan ZX, Gao YT, Zheng W: Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 2005, 65 (12): 5015-5019. 10.1158/0008-5472.CAN-04-2786.CrossRefPubMed
20.
Masago K, Fujita S, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Ichikawa M, Mio T, Mishima M: Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci. 2009, 100 (10): 1917-1922. 10.1111/j.1349-7006.2009.01253.x.CrossRefPubMed
21.
Chen MH, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS: VEGF -460T -- > C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenomics J. 2010.
22.
Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A: The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 117 (1): 109-116. 10.1016/j.ygyno.2009.11.011.
23.
Formento JL, Etienne-Grimaldi MC, Francoual M, Pages G, Onesto C, Formento P, Chamorey E, Dassonville O, Poissonnet G, Milano G: Influence of the VEGF-A 936C > T germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics. 2009, 10 (8): 1277-1283. 10.2217/pgs.09.54.CrossRefPubMed
24.
Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, Karakitsos P: Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog. 2009, 48 (6): 563-569. 10.1002/mc.20495.CrossRefPubMed
25.
Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, Asomaning K, Wang Z, Su L, Heist RS: Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res. 2009, 15 (14): 4680-4685. 10.1158/1078-0432.CCR-09-0192.CrossRefPubMedPubMedCentral
26.
Kim JG, Sohn SK, Chae YS, Cho YY, Bae HI, Yan G, Park JY, Lee MH, Chung HY, Yu W: Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007, 18 (6): 1030-1036. 10.1093/annonc/mdm085.CrossRefPubMed
27.
Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol. 2007, 52 (4): 1147-1155. 10.1016/j.eururo.2007.01.073.CrossRefPubMed
28.
Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G, Pikoulis E, Tsigris C, Karakitsos P, Peros G: Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006, 94 (7): 624-630. 10.1002/jso.20619.CrossRefPubMed
Metadata
Title
Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy
Authors
Xiaoxiang Guan
Ming Yin
Qingyi Wei
Hui Zhao
Zhensheng Liu
Li-E Wang
Xianglin Yuan
Michael S O'Reilly
Ritsuko Komaki
Zhongxing Liao
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-431

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells

Case report

Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor

Research article

Expression of BMI-1 and Mel-18 in breast tissue - a diagnostic marker in patients with breast cancer

Research article

Deregulation of manganese superoxide dismutase (SOD2) expression and lymph node metastasis in tongue squamous cell carcinoma

Hypothesis

Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?

Research article

Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits